Lenacapavir Injection Shows 96% Efficacy in Preventing HIV

Twice-yearly injectable drug outperforms daily Truvada pill in major clinical trials, but high cost raises accessibility concerns.

Gilead Sciences' lenacapavir demonstrated 96% efficacy in preventing HIV infections in the PURPOSE 2 phase 3 trial.
The trial included over 3,250 participants from diverse backgrounds across multiple countries, highlighting its potential global impact.
Lenacapavir was significantly more effective than the daily Truvada pill, showing an 89% higher efficacy rate.
Despite its effectiveness, the high cost of lenacapavir raises concerns about accessibility, particularly in low-resource regions.
Gilead plans to seek regulatory approval for lenacapavir as PrEP by the end of the year, aiming for a market release by mid-to-late 2025.